About Orchid
Orchid is a company based in Armadale (Australia) founded in 2019. It operates as a HealthTech. Orchid has raised $16.5 million across 2 funding rounds from investors including 23andMe, LIfT Biosciences and Prometheus Fund. Orchid offers products and services including Embryo Report and Couple Report. Orchid operates in a competitive market with competitors including Immunosis, The Gene Council, Genepath and Private Genetic Health, among others.
- Headquarter Armadale, Australia
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.5 M (USD)
in 2 rounds
-
Latest Funding Round
$12 M (USD), Series A
Dec 05, 2023
-
Investors
23andMe
& 16 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orchid
Orchid offers a comprehensive portfolio of products and services, including Embryo Report and Couple Report.
Advanced genetic screening for embryos during IVF process.
Preconception test for child’s genetic disease predisposition.
People of Orchid
Unlock access to complete
Unlock access to complete
Funding Insights of Orchid
Orchid has successfully raised a total of $16.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $12 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Orchid
Orchid has secured backing from 17 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include 23andMe, LIfT Biosciences and Prometheus Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
An investment fund focused on undervalued securities is managed.
|
Locked | Locked | Locked | |
|
Seed and early-stage investments are made across US and India.
|
Locked | Locked | Locked | |
|
Technical founders are supported by Pebblebed through early investments.
|
Locked | Locked | Locked |
Investor details for Orchid
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orchid
Investment portfolio details for Orchid
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Orchid
Detailed financials for Orchid
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orchid Comparisons
Peer comparison for Orchid
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orchid
Orchid operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Immunosis, The Gene Council, Genepath and Private Genetic Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of a diagnostic platform for diagnosing patients with immune dysfunctions
|
|
| Locked | Locked | Locked |
Offers private genetic testing and counselling for cancer risk, with online appointments and expert advice.
|
|
| Locked | Locked | Locked |
Provides targeted gene sequencing for newborn screening and health detection.
|
|
| Locked | Locked | Locked |
Provides genetic counselling, testing, and education for families with health conditions.
|
Detailed competitors of Orchid
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orchid
Complete news archive for Orchid
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orchid
Orchid was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Orchid is headquartered in Armadale, Australia. It is registered at Armadale, Victoria, Australia.
Orchid is a funded company, having raised a total of $16.5M across 2 funding rounds to date.
Whole genome screening for embryos during IVF is offered by Orchid to detect genetic risks for severe diseases before pregnancy. Services include the Embryo Report for advanced genetic screening and the Couple Report for preconception genetic predisposition testing. Risks for monogenic and polygenic diseases, neurodevelopmental disorders, cancers, and birth defects are identified using over 99 of an embryos DNA data. Solutions are tailored for patients and clinicians in the reproductive health sector.
Orchid's top competitors include Immunosis, The Gene Council and Genepath.
Orchid offers Embryo Report and Couple Report.
Orchid has 17 investors. Key investors include 23andMe, LIfT Biosciences, Prometheus Fund, Refactor Capital, and Pebblebed.